-
公开(公告)号：US20220306635A1
公开(公告)日：2022-09-29
申请号：US17068574
申请日：2020-10-12
Applicant: Genentech, Inc. , NewLink Genetics Corporation
Inventor： Xingyu Lin , Po-wai Yuen , Rohan Mendonca , Brendan Parr , Richard Pastor , Zhonghua Pei , Lewis Gazzard , Firoz Jaipuri , Sanjeev Kumar , Xiaokai Li , Roheeth Pavana , Hima Potturi , Venkata Velvadapu , Jesse Waldo , Zuhui Zhang , Guosheng Wu , Benjamin Douglas Sellers
IPC: C07D487/04 , A61P35/00 , A61K38/16 , A61K45/06 , C07D519/00
Abstract: Presently provided are inhibitors of cellularly expressed TD02 and pharmaceutical compositions thereof, useful for modulating an activity of tryptophan 2, 3 dioxygenase; treating immunosuppression; treating a medical conditions that benefit from the inhibition of tryptophan degradation; enhancing the effectiveness of an anti-cancer treatment comprising administering an anti-cancer agent; and treating tumor-specific immunosuppression associated with cancer.
-
公开(公告)号：US10316023B2
公开(公告)日：2019-06-11
申请号：US15449706
申请日：2017-03-03
Applicant: GENENTECH, INC. , CONSTELLATION PHARMACEUTICALS, INC.
Inventor： Brian K. Albrecht , Alexandre Cote , Terry Crawford , Martin Duplessis , Andrew Charles Good , Yves LeBlanc , Steven Magnuson , Christopher G. Nasveschuk , Richard Pastor , F. Anthony Romero , Alexander M. Taylor
IPC: C07D249/12 , C07D403/04 , C07D403/12 , C07D401/04 , C07D401/12 , A61K31/53 , A61K31/4196 , A61P35/00 , C07D253/075 , A61K45/06
Abstract: The present invention relates to methods for treating PCAF mediated disorders using a compound of formula (I) or a pharmaceutically acceptable salt thereof: wherein R1, R3-R6, X, and each Re have any of the values defined in the specification. Also included are novel compounds of formula (I) and salts thereof, as well as pharmaceutical compositions comprising a compound of formula (I) or a pharmaceutically acceptable salt thereof.
-
公开(公告)号：US20190016726A1
公开(公告)日：2019-01-17
申请号：US16065397
申请日：2016-12-23
Applicant: Genentech, Inc. , NewLink Genetics Corporation
Inventor： Xingyu Lin , Po-wai Yuen , Rohan Mendonca , Brendan Parr , Richard Pastor , Zhonghua Pei , Lewis Gazzard , Firoz Jaipuri , Sanjeev Kumar , Xiaokai Li , Roheeth Pavana , Hima Potturi , Venkata Velvadapu , Jesse Waldo , Zuhui Zhang , Guosheng Wu
IPC: C07D487/04 , A61P35/00 , C07D519/00 , A61K38/16
Abstract: Presently provided are inhibitors of cellularly expressed TDO2 and pharmaceutical compositions thereof, useful for modulating an activity of tryptophan 2, 3 dioxygenase; treating immunosuppression; treating a medical conditions that benefit from the inhibition of tryptophan degradation; enhancing the effectiveness of an anti-cancer treatment comprising administering an anti-cancer agent; and treating tumor-specific immunosuppression associated with cancer.
-
公开(公告)号：US20170312292A1
公开(公告)日：2017-11-02
申请号：US15482581
申请日：2017-04-07
Applicant: GENENTECH, INC. , CONSTELLATION PHARMACEUTICALS, INC.
Inventor： Anthony F. Romero , Steven R. Magnuson , Richard Pastor , Vickie Hsiao-Wei Tsui , Jeremy Murray , Terry Crawford , Daniel J. Burdick , Brian K. Albrecht , Alexandre Cote , Alexander M. Taylor , Christopher G. Nasveschuck , Yves LeBlanc , Michael Charles Hewitt , Kwong Wah Lai , Kevin Chen
IPC: A61K31/55 , C07D403/04 , C07D243/24 , A61K31/5513 , C07D243/12 , C07D223/16 , C07D403/14 , C07D267/14
CPC classification number: A61K31/55 , A61K31/337 , A61K31/5513 , A61K45/06 , C07D223/16 , C07D243/12 , C07D243/24 , C07D267/14 , C07D401/06 , C07D401/12 , C07D401/14 , C07D403/04 , C07D403/06 , C07D403/14 , C07D405/04 , C07D405/12 , C07D413/04 , C07D413/10 , C07D471/04 , C07D495/04 , A61K2300/00
Abstract: The present invention relates to compounds of formula (I): and to salts thereof, wherein A has any of the values defined in the specification, and compositions and uses thereof. The compounds are useful as inhibitors of CBP and/or EP300. Also included are pharmaceutical compositions comprising a compound of formula (I) or a pharmaceutically acceptable salt thereof, and methods of using such compounds and salts in the treatment of various CBP and/or EP300-mediated disorders.
-
公开(公告)号：US20170275289A1
公开(公告)日：2017-09-28
申请号：US15449692
申请日：2017-03-03
Applicant: GENENTECH, INC. , CONSTELLATION PHARMACEUTICALS, INC.
Inventor： Brian K. Albrecht , Alexandre Cote , Terry Crawford , Martin Duplessis , Andrew Charles Good , Yves LeBlanc , Steven Magnuson , Christopher G. Nasveschuk , Richard Pastor , Anthony F. Romero , Alexander M. Taylor
IPC: C07D487/04 , A61K31/5025 , C07D237/34 , A61K31/502 , A61K31/5377 , C07D403/12 , C07D401/12 , A61K31/55 , C07D405/12 , C07D471/04 , C07D237/32
CPC classification number: C07D487/04 , A61K31/502 , A61K31/5025 , A61K31/5377 , A61K31/55 , C07D237/32 , C07D237/34 , C07D401/12 , C07D403/12 , C07D405/12 , C07D471/04
Abstract: The present invention relates to methods for treating PCAF and GCN5 mediated disorders using a compound of formula (I) or a pharmaceutically acceptable salt thereof: wherein ring A, R1, R3, R4, R5, and each Re have any of the values defined in the specification. Also included are novel compounds of Formula (I) and salts thereof, as well as pharmaceutical compositions comprising a compound of formula (I) or a pharmaceutically acceptable salt thereof.
-
Patent Agency Ranking
公开(公告)号：US11827639B2
公开(公告)日：2023-11-28
申请号：US16626191
申请日：2018-06-28
Applicant: Genentech, Inc. , NewLink Genetics Corporation
Inventor： Zhonghua Pei , Brendan Parr , Wendy Liu , Richard Pastor , Lewis Gazzard , Firoz Jaipuri , Sanjeev Kumar , Hima Potturi , Guoshen Wu , Xingyu Lin , Yanyan Chu , Powai Yuen
IPC: C07D487/04 , A61K31/4188 , A61K31/438 , A61K31/439 , A61K31/4439 , A61K31/454 , A61K31/437 , A61K31/4725 , A61K31/5377 , A61K45/06
CPC classification number: C07D487/04
Abstract: Presently provided are inhibitors of TD02 and IDO1 and pharmaceutical compositions thereof, useful for modulating an activity of tryptophan 2,3 dioxygenase and indoleamine 2,3-dioxygenase 1; treating immunosuppression; treating a medical conditions that benefit from the inhibition of tryptophan degradation; enhancing the effectiveness of an anti-cancer treatment comprising administering an anti-cancer agent; and treating tumor-specific immunosuppression associated with cancer.
-
公开(公告)号：US11279735B2
公开(公告)日：2022-03-22
申请号：US16816969
申请日：2020-03-12
Applicant: Genentech, Inc.
Inventor： Emily J. Hanan , Georgette Castanedo , Marie Gabrielle Braun , Keira Garland , Peter Andrew Smith , Richard Pastor , Paul Gibbons , Yunxing Cheng , Guosheng Wu , Yuhong Fu , Po-Wai Yuen
Abstract: Provided herein are antibacterial compounds, wherein the compounds in some embodiments have broad spectrum bioactivity. In various embodiments, the compounds act by inhibition of lipoprotein signal peptidase II (LspA), a key protein in bacteria. Pharmaceutical compositions and methods for treatment using the compounds described herein are also provided.
-
公开(公告)号：US10206931B2
公开(公告)日：2019-02-19
申请号：US15482581
申请日：2017-04-07
Applicant: GENENTECH, INC. , CONSTELLATION PHARMACEUTICALS, INC.
Inventor： F. Anthony Romero , Steven R. Magnuson , Richard Pastor , Vickie Hsiao-Wei Tsui , Jeremy Murray , Terry Crawford , Daniel J. Burdick , Brian K. Albrecht , Alexandre Cote , Alexander M. Taylor , Christopher G. Nasveschuck , Yves LeBlanc , Michael Charles Hewitt , Kwong Wah Lai , Kevin Chen
IPC: A61K31/551 , C07D243/12 , C07D403/04 , C07D403/14 , A61K31/55 , C07D223/16 , C07D267/14 , C07D401/14 , C07D401/06 , C07D401/12 , C07D403/06 , C07D405/04 , C07D405/12 , C07D413/04 , C07D413/10 , C07D243/24 , C07D471/04 , C07D495/04 , A61K45/06 , A61K31/337 , A61K31/5513
Abstract: The present invention relates to compounds of formula (I): and to salts thereof, wherein A has any of the values defined in the specification, and compositions and uses thereof. The compounds are useful as inhibitors of CBP and/or EP300. Also included are pharmaceutical compositions comprising a compound of formula (I) or a pharmaceutically acceptable salt thereof, and methods of using such compounds and salts in the treatment of various CBP and/or EP300-mediated disorders.
-
公开(公告)号：US20180022727A1
公开(公告)日：2018-01-25
申请号：US15643808
申请日：2017-07-07
Applicant: GENENTECH, INC. , CONSTELLATION PHARMACEUTICALS, INC.
Inventor： Brian K. Albrecht , Alexandre Cote , Victor Gehling , Vickie Hsiao-Wei Tsui , James Richard Jr. Kiefer , Jun Liang , Steven Magnuson , Christopher G. Nasveschuk , Richard Pastor , F. Anthony Romero , Alexander M. Taylor , Birong Zhang
IPC: C07D401/06 , C07D241/04 , C07D211/30 , C07D413/06
CPC classification number: C07D401/06 , C07D211/30 , C07D241/04 , C07D405/06 , C07D409/06 , C07D413/06
Abstract: The present invention relates to compounds useful as inhibitors of one or more histone demethylses, such as KDM2b. The invention also provides pharmaceutically acceptable compositions comprising compounds of the present invention and methods of using said compositions in the treatment of various disorders.
-
公开(公告)号：US20170333406A1
公开(公告)日：2017-11-23
申请号：US15667227
申请日：2017-08-02
Applicant: GENENTECH, INC. , CONSTELLATION PHARMACEUTICALS, INC.
Inventor： Marc Adler , Brian K. Albrecht , Sarah Bronner , Kevin X. Chen , Alexandre Côté , Terry Crawford , Patrick Cyr , Jackson Egen , Steven Kauder , Kwong Wah Lai , Jiangpeng Liao , Steven Magnuson , Jeremy Murray , Richard Pastor , F. Anthony Romero , Alexander M. Taylor , Vickie Hsiao-Wei Tsui , Fei Wang , Bing-Yan Zhu
IPC: A61K31/437 , C07D471/04 , A61K45/06 , A61K31/55 , A61K31/5415 , A61K31/5377 , A61K31/4375 , A61K31/506 , A61K31/498 , A61K31/496 , A61K31/4725 , A61K31/4709 , C07D519/00 , A61K31/538
CPC classification number: A61K31/437 , A61K31/4375 , A61K31/4709 , A61K31/4725 , A61K31/496 , A61K31/498 , A61K31/506 , A61K31/5377 , A61K31/538 , A61K31/5415 , A61K31/55 , A61K45/06 , C07D471/04 , C07D519/00
Abstract: The present invention relates to compounds of formula (I) or formula (II): and to salts thereof, wherein R1-R4 of formula (I) and R1-R3 of formula (II) have any of the values defined herein, and compositions and uses thereof. The compounds are useful as inhibitors of CBP and/or EP300. Also included are pharmaceutical compositions comprising a compound of formula (I) of formula (II) or a pharmaceutically acceptable salt thereof, and methods of using such compounds and salts in the treatment of various CBP and/or EP300-mediated disorders.
-
-
-
-
-
-
-
-
-
Search Results
34
records
(took 0.027 seconds)
